Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Because Momentum and Elevate Plans include a larger quantity of medication, we strongly recommend that new patients first try a Monthly or Tier Plan to ensure tolerance and response to the specific formulation
BPC-157 came off the FDA Category 2 list effective April 23, 2026, and is one of the seven peptides under PCAC review for 503A compounding eligibility in July 2026
The compound has progressed through Phase I and Phase II trials with promising results, demonstrating both efficacy and safety in multiple patient populations
Once again, GHK-Cu appeared to mediate its effects through decreased TNF-alpha and IL-6 expression [11]
